| Ytd | 7.52% | |
| 1y | 7.79% |
| Open | 8.45 | Prev Close | 8.48 | Low | 8.29 | High | 8.47 | Mkt Cap | 1.54B |
| Vol | 1.40M | Avg Vol | 1.87M | EPS | -0.10 | P/E | N/A | Forward P/E | 21.64 |
| Beta | 0.85 | Short Ratio | 5.33 | Inst. Own | 59.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 8.26 | 200-d Avg | 7.01 | 1yr Est | 11.71 |
XERS News
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendati
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth ac
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweig
Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a y
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the q
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed t
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 mi
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The lates
Please replace the release issued earlier today with the following corrected version that provides a
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the f
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-grow
CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.
Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdin
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu
Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment
Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 mi
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the
HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)
Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $36
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the
Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to
HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)
Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) wit
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2025 sales outlook from $280.000 million-$290.000 mi
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly sales of $74.380 million which beat the an
First concentrated, ready-to-dilute liquid glucagon available for diagnostic proceduresSHIRLEY, N.Y.
HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) wit
Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outpe
First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterolog
Piper Sandler analyst David Amsellem reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Neu
HC Wainwright & Co. analyst Oren Livnat reiterates Xeris Biopharma Holdings (NASDAQ:XERS) wit